Bionas and PRIMACYT to cooperate on cell-based assay for prediction of hepatotoxic effects of drugs and chemicals
Advertisement
Bionas and PRIMACYT have entered into a cooperation aimed at the development of a cell-based assay using primary human hepatocytes for prediction of hepatotoxic effects in response to test compounds.
Primary human hepatocytes, provided by PRIMACYT, are cultivated directly on collagen-coated Bionas® metabolic chips. The chips are then placed into the Bionas analyzing system to evaluate the effect of test compounds. After a recovery period the hepatocytes can be re-used for further experiments.
Predicting liver toxicity is a major concern of the pharmaceutical industry and non-immortalized primary human hepatocytes can be used as biosensors for the analysis of drugs, food additives and chemicals.
Most read news
Organizations
Other news from the department business & finance
These products might interest you
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.